Transplant-related mortality (TRM) following allogeneic bone marrow transplantation (BMT) remains a major concern and early identification of patients at risk may be clinically relevant. In this study we describe a predictive score based on bilirubin and blood urea nitrogen (BUN) levels on day +7 after BMT. The patient population consisted of 309 consecutive patients who underwent BMT from sibling (n = 263) or unrelated donors (n = 46) for hematologic disorders between December 1990 and December 1996. Of 27 laboratory tests taken on day +7 after BMT, serum bilirubin (P = 0.02) and BUN (P = 0.007) were found to be independent predictors of TRM in multivariate analysis. The median levels of bilirubin (0.9 mg/dl) and of BUN (21 mg/dl) were then used as a cut-off and a score of 1 was given for values equal/greater than the median. There were 216 patients with scores 0-1 (low risk) on day +7 (bilirubin Ͻ0.9 and/or BUN Ͻ21) and 93 patients with score 2 (high risk) (bilirubin у0.9 and BUN у21): the latter had more grade III-IV acute graft-versus-host disease (P = 0.03), slower neutrophil (P = 0.02) and slower platelet engraftment (P = 0.002). The actuarial 5 year TRM is 22% for low risk vs 44% for high risk patients (P = 0.0003). For HLA-identical siblings TRM is 20% vs 35% (P = 0.01), for unrelated donors it is 20% vs 65% (P = 0.01). Day +7 score was highly predictive of TRM on multivariate analysis (hazard ratio 1.9, P Ͻ 0.01), after adjustment for year of transplant (P Ͻ 0.00001), unrelated vs sibling donors (P = 0.001), patient age (P = 0.01) and diagnosis (P = 0.01). These results were validated on an independent group of 82 allogeneic BMT recipients in a pediatric Unit who showed an actuarial TRM of 16% for low risk vs 46% for high risk patients (P = 0.002). This study suggests that it may be possible to identify patients with different risks of TRM on day +7 after BMT: high risk patients could be Allogeneic bone marrow transplantation (BMT) is associated with considerable morbidity and mortality, and several studies have addressed the issue of risk factors for major single complications such as interstitial pneumonitis, 1 acute GVHD 2,3 and graft rejection: 4 patient variables (older age), donor variables (older age, parous female donors for male recipients, degree of HLA matching) and transplant variables (longer interval from diagnosis to transplant, intensive regimens), are among these. A study from the Seattle group has looked at risk factors for veno-occlusive disease of the liver, another important complication of allogeneic BMT 5 and found that early increments in serum bilirubin level and body weight were highly predictive. Other studies have also addressed the impact of risk factors on post-BMT complications. [6] [7] [8] [9] [10] During the past decades we have improved our ability to prevent and/or treat such complications, and transplantrelated mortality (TRM) has been considerably reduced 11 and delayed: in our HLA-identical sibling program TRM was 39% before 1990 (385 patients) and occurred at a median interval of 48 days from BMT (range 1-1230); TRM is currently 17% (333 patients) with a median interval from transplant of 103 days (range 8-1419) (P Ͻ 0.00001) (unpublished). Very few patients die before day +7: the 10th percentile is currently day 30, and the 75th percentile is day 202. The remaining 25% late mortality is scattered between 203 and 1419 days post BMT (unpublished). Delayed TRM is associated with emerging problems such as thrombotic thrombocytopenic purpura (TTP)-like syndromes, also known as thrombotic microangiopathy (TMA) 12,13 possibly associated with cytokine and druginduced endothelial damage.
Allogeneic bone marrow transplantation (BMT) is associated with considerable morbidity and mortality, and several studies have addressed the issue of risk factors for major single complications such as interstitial pneumonitis, 1 acute GVHD 2,3 and graft rejection: 4 patient variables (older age), donor variables (older age, parous female donors for male recipients, degree of HLA matching) and transplant variables (longer interval from diagnosis to transplant, intensive regimens), are among these. A study from the Seattle group has looked at risk factors for veno-occlusive disease of the liver, another important complication of allogeneic BMT 5 and found that early increments in serum bilirubin level and body weight were highly predictive. Other studies have also addressed the impact of risk factors on post-BMT complications. [6] [7] [8] [9] [10] During the past decades we have improved our ability to prevent and/or treat such complications, and transplantrelated mortality (TRM) has been considerably reduced 11 and delayed: in our HLA-identical sibling program TRM was 39% before 1990 (385 patients) and occurred at a median interval of 48 days from BMT (range 1-1230); TRM is currently 17% (333 patients) with a median interval from transplant of 103 days (range 8-1419) (P Ͻ 0.00001) (unpublished). Very few patients die before day +7: the 10th percentile is currently day 30, and the 75th percentile is day 202. The remaining 25% late mortality is scattered between 203 and 1419 days post BMT (unpublished). Delayed TRM is associated with emerging problems such as thrombotic thrombocytopenic purpura (TTP)-like syndromes, also known as thrombotic microangiopathy (TMA) 12, 13 possibly associated with cytokine and druginduced endothelial damage. 14 Therefore, in current allogeneic transplant programs, most patients are in relatively good clinical condition in the first weeks after BMT during the period of neutropenia, and tend to have problems later: a number of patients will, indeed, develop serious life-threatening complications, especially in the unrelated transplant setting.
We therefore asked whether we could predict TRM while the transplant was ongoing, at the time when most patients are well: we wanted the model to be based on laboratory values, rather than subjective clinical judgment, and we wanted it to be very early in the course of the transplant. We now report a predictive model based on 309 patients, and validated on 82 independent transplants performed in a different hospital.
Materials and methods

Data collection
Laboratory and clinical data have been collected prospectively since 1990, during the admission of patients to hospital and during examinations as out-patients. We had 27 laboratory variables: (1) hemoglobin (gr%), (2) hematocrit (%), (3) mean corpuscular volume (pg/l), (4) white blood cells (× 10 9 /l), (5) neutrophils (%), (6) lymphocytes (%), (7) monocytes (%), (8) platelets (× 10 9 /l), (9) glycemia (mg/dl), (10) blood urea nitrogen (mg/dl), (11) creatinine (mg/dl), (12) bilirubin (mg/dl), (13) alanine transferase (IU/l), (14) aspartate transferase (IU/l), (15) lactic dehydrogenase (IU/l), (16) alkaline phosphatase (IU/l), (17) sodium (mEq/l), (18) potassium (mEq/l), (19) total protein (gr%), (20) albumin (gr%), (21) IgG (mg/dl), (22) IgA (mg/dl), (23) IgM (mg/dl), (24) cholinesterase, (25) cholesterol, (26) triglicerides, (27) gamma glutyl transferase, collected at least once a week from day −7 to day +30 and then at each assessment as an out-patient up to the last follow-up. This produces a dynamic data-base with an unlimited number of records/patient. It gives the opportunity to look at laboratory tests at any given time pre or post BMT, and correlate these tests with clinical outcome.
Patients
Patients had received a bone marrow transplant from an HLA-identical sibling (n = 263) or a matched unrelated donor (MUD) (n = 46) and were alive on day +7 after BMT. Clinical data are outlined in Table 1 . Conditioning regimens included cyclophosphamide (CY) 120 mg/kg and total body irradiation (TBI) (9.9-12 Gy) (n = 256), CY 200 mg/kg (n = 28) and CY 120 mg/kg followed by thiotepa (TT) 15 mg/kg (n = 25). The bone marrow was always given unmanipulated. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine (CyA) alone in 52 patients and CyA + methotrexate (MTX) in 257. Transplant protocols and management of patients have been described. 15 Patients were grafted between 15 June 1990 and 31 December 1996, so that minimum follow-up on survivors is 18 months at the time of analysis.
Transplant-related mortality (TRM)
The major end point of this study was the effect of laboratory tests on TRM, defined as death due to any transplantrelated complication. Thus, patients experiencing relapse of the original disease were censored as surviving at the time of relapse.
Data analysis
Step 1: The Wilcoxon Mann-Whitney test for non-paired groups was used to test whether a given variable had significantly different values on day +7 after BMT in patients who subsequently died of transplant-related complications (TRM yes) as compared to patients who survived the transplant (TRM no). Only P values of less than 0.01 were considered predictive.
Step 2: We then tested the predictive variables in a multivariate COX model together with patient-related (age gender), disease-related (diagnosis, phase, interval diagnosis-BMT) and transplant-related variables (type age gender of donor, year of transplant, number of cells grafted), to prove that the predictive laboratory test were still significant.
Step 3: day +7 score: Bilirubin serum levels and blood urea (BUN) were the two chosen variables with significant different values in the Mann-Whitney test, when comparing patients surviving or not (P Ͻ 0.0001). The median value for each of them was then calculated: it was 0.9 mg/dl for bilirubin , and 21 mg/dl for BUN. A score of 1 was assigned for each value equal or greater than the median, and patients were classified as low risk (scores 0-1) or high risk (score 2) as follows: low risk (scores 0-1) = (bilirubin Ͻ0.9 and/or BUN Ͻ21), 216 patients; high risk (score 2) = (bilirubin у0.9 and BUN у21), 93 patients.
Validation patient group
Eighty-two patients transplanted in a pediatric unit (Ospedale Gaslini, Genova) were used as a validation group: median patient age was 8 (range 1-16) and they were grafted between 1990 and 1997 from HLA identical (n = 54) or unrelated donors (n = 28) ( Table 1) .
Survival curves and the COX model
Survival curves were estimated according to Kaplan and Meier. 16 To estimate the effect of the day +7 score, adjusted for possible confounding factors, we used the Cox model. First the day +7 score was introduced as a stratifying factor (so as not to assume proportionality), and the potential confounding factors were introduced in a forward stepwise procedure. After that, another model was fitted in which the day +7 score was not used as a stratifying variable but as a categorical covariate: the coefficients of the covariates and the actual curves were identical in both models. Thus the day +7 score was used as a covariate. All interaction terms between the day +7 score and the other covariates were tested in a backward stepwise procedure and none were retained (P values Ͼ0.5). Finally, proportionality was tested by introducing a time-dependent covariate categorizing time in two categories. Inspection of the hazard plots failed to reveal any deviation from the proportionality hazard assumption. Hence, the simple model with the predictive score and all confounders as main terms, was used as an adequate description of the predictive ability of the model. Figure 1 outlines the mean values of BUN with 95% confidence intervals for patients who survived or subsequently died of transplant-related complications: the two curves start to be significantly different on day +5 (P = 0.04) and diverge more so on days +7, +9, +11 and day +13 after BMT. Figure 2 depicts the same difference for bilirubin: here, the curves start to diverge 2 days later, on day +7. Table 2 outlines the median value of serum bilirubin and blood urea nitrogen on day +7 and its predictive effect in multivariate analysis; it also shows that the combined use of bilirubin and BUN increased the predictive effect on TRM.
Results
Blood urea nitrogen (BUN) and bilirubin
Day +7 score
There were 216 patients classified as low risk on day +7 (scores 0-1) (bilirubin у0.9 mg/dl or BUN у21 mg/dl) and 93 patients classified as high risk (score 2). Table 3 details the clinical characteristics of patients with scores 0-1 and 2: there were more patients at high risk in the unrelated donor group (P = 0.03). There was also a tendency for high risk patients to be older and to have received Days from BMT P=0.04 P=0.004 P=0.005 P=0.003 P=0.0000
Figure 1 Blood urea nitrogen (BUN) mean serum levels (mg/dl) with 95% confidence intervals in patients who survived (--) or subsequently died (----) of transplant-related complications. P values (Student's t-test) are indicated when significant. Increasing difference between the two curves is seen starting on day +5 after bone marrow transplantation (BMT). Days from BMT P = 0.05 P = 0.02 P = 0.002 P = 0.008
Figure 2
Bilirubin serum levels (mg/dl) with 95% confidence intervals in patients who survived (--) or subsequently died (----) of transplantrelated complications. P values (Student's t-test) are indicated when significant. a lower number of cells at transplant, but not significantly (Table 3) . Otherwise, the distribution of donor age and gender, recipient gender, diagnosis, interval diagnosis-transplant, and phase of the disease was similar in the two risk groups. Also, the year of transplant was not significantly different. Patients prepared for BMT with conditioning regimens including total body irradiation (TBI) were equally distributed: the same was true for patients treated with CyA alone or CyA + MTX for GVHD prophylaxis ( Table  3 ). The median value of bilirubin in the two groups was 0.7 mg/dl (range 0.1-4.2) vs 1.3 mg/dl (0.9-7.5) (P Ͻ 0.00001); for BUN it was 19 mg/dl (5-96) vs 25 mg/dl (21-88) (P Ͻ 0.00001), for creatinine it was 0.8 mg/dl (0.2-9) vs 0.9 mg/dl (0.3-7.9) (P = 0.1).
Outcome of patients scored on day +7 Table 4 outlines the overall outcome of patients scored on day +7: when compared to patients with scores 0-1, patients with score 2 had delayed neutrophil engraftment and lower median platelet counts especially in the interval of days 0-20 and days 51-100 after BMT; they also had more grade III-IV acute GVHD (P = 0.03) High risk patients also had a greater number of CMV antigen-positive cells (× 10 5 ) at diagnosis of the infection (10 vs 6) although not significantly (P = 0.2), and a significantly greater number of maximum positive cells during the infection (21 vs 9, P = 0.03). High risk patients had significantly greater TRM (P = 0.0003). More patients with score 2 died of GVHD, of infections and of other causes including multior- Table 4 Outcome of patients scored on day +7 gan failure (P = 0.001). The actuarial 5 year TRM in this group of patients is 22% for low risk vs 44% for high risk patients (P = 0.0003) (Figure 3 ). The predictive scoring system was then applied to an independent group of 82 patients: 62 patients were scored as 0-1 and had an actuarial TRM of 16% compared to 46% for 20 patients with score 2 (P = 0.002) (Figure 3 ). Day +7 score was predictive when used separately in HLA-identical siblings: 190 and 73 patients were respectively scored as 0-1 or 2 and their TRM is 20% vs 35% (P = 0.01). Similarly for unrelated donors TRM was 20% vs 65% (P = 0.01).
Early and late mortality
Day +7 score was also predictive if one analyzed separately the risk of TRM within day +100 (10% vs 28%, P = 0.006) or beyond day +100 (15% vs 30% TRM, P = 0.004). Therefore, it predicted early as well as late transplant complications.
Sensitivity and specificity of day +7 score
On day +7 the sensitivity of the scoring system was 47% and the specificity 75%.
Multivariate COX analysis
We then entered the day +7 score in a multivariate COX analysis including patient-related, disease-related and transplant-related variables: significant variables were year of transplant (P Ͻ 0.00001), unrelated vs sibling donors (P = 0.001), day +7 score (P = 0.004), patient age (P = 0.01) and diagnosis (P = 0.01). In this model other variables were not predictive: recipient sex (P = 0.06), phase of the disease (P = 0.1), donor age (P = 0.1), cell dose (P = 0.4), interval diagnosis BMT (P = 0.6), donor sex (P = 0.6). We can Days of follow-up therefore conclude that day +7 score predicts TRM with an estimated relative risk of 1.9 (95% CI = 1.2-3.1) for high score patients, after adjusting for age, calendar year and donor type. The risk of TRM for patients with acute leukemia in the study group and validation group is depicted in Figure 4 .
Predictive model for the individual patients
If one wishes to assess the risk of TRM for an individual patient with specific covariate values, we have prepared the model on a Web Server at the address http//WWW.CLINICALRESEARCH.NL/EBMT/MODELS/. When loading this model one can choose among significant variables (age, donor type and diagnosis) and actually draw the projected risk of TRM in the individual patient for both high and low risk scores.
Discussion
We have shown in this study that a blood level of у21 mg/dl for urea nitrogen (BUN) and bilirubin level of у0.9 mg/dl on day +7 after BMT, identifies patients at greater risk (1.9) of transplant-related mortality. This result emerged from univariate and multivariate analysis of 309 allogeneic BMT recipients and was validated on 82 transplants performed in a different hospital. We wanted a predictive score to be based on simple laboratory values, therefore objective, and assessed early in the course of the transplant. Serum bilirubin and BUN on day +7 post graft seemed to fulfill all three requirements, and median values could discriminate patients at different risk of transplant-related complications. We were impressed with the fact that BUN rises slightly but significantly, very early during the conditioning regimen in patients who will then die of transplant-related complications, such that on day +7 the 95% confidence intervals do not overlap any longer. The difference between these two groups increases from day +7 to day +13 after BMT (P Ͻ 0.00001), suggesting one could also use day +13 BUN and bilirubin levels to score patients. Against this option is the fact that by day +13 some patients will have developed GVHD and it may be too late for early intervention: indeed the median time for starting GVHD therapy in a recent prospective trial was day +12 after BMT, and intensity of therapy did not seem to have a significant impact at that time. 17 The second reason for using day +7 BUN levels was that the sensitivity was only slightly increased on day +13. If we want a predictive score, we argued the sooner the better. Bilirubin levels seem to take off with a delay of a couple of days in patients who will then develop transplant complications. It was rewarding to see that median levels of BUN and bilirubin were highly predictive in univariate and multivariate analysis, and this allowed a large number of patients to be included in the high and low risk groups. Now, the first question is the following: is the high score identifying a subgroup of patients with advanced leukemia, old age, transplanted from alternative donors some years ago; in that case it would be of little help, because of the presence of well known risk factors. We therefore looked at the distribution of patient, disease and transplant variables in low risk and high risk patients, and found that although high risk patients were older with more advanced disease, this did not reach statistical significance, and other variables such as the year of transplant were equally distributed in the two groups. We do not want to imply that age has no impact on outcome, but rather that we still have patients at high risk of death also in the most recent transplant programs, even in the young group, even in patients with early disease. There was one exception, that is donor type: we had significantly more high risk patients in the unrelated donor group (P = 0.03), although the latter could also be subdivided into high risk and low risk patients according to bilirubin and BUN level. Therefore, it seems that the day +7 score is identifying a group of patients who happened to develop early signs of toxicity in the absence of pre-transplant risk factors, such as old age or year of transplant or disease status.
The second question concerns the outcome of patients scored on day +7 after BMT: why are high risk patients doing worse. We saw significantly more acute GVHD (grades III-IV) in the high risk group, significantly delayed neutrophil engraftment, significantly lower platelet counts and more CMV. One could argue that acute GVHD is enough to account for all these clinical effects, and therefore that day +7 score is simply a predictor of aGVHD. This is true to some extent, but increased TRM in high risk patients is caused by more aGVHD but especially by more infections, and more multiorgan failure, as suggested by analyzing the causes of death in the two groups.
Then we come to the main objective of the study: is the day +7 score really predictive of transplant-related mortality. It seemed so in every way we looked at the data: day +7 BUN and bilirubin levels are significantly higher in patients with TRM, the median values identify patients at risk in univariate and multivariate analysis, the combined use of BUN and bilirubin increases the predictive effect. The actuarial TRM of patients with low scores is significantly different from the actuarial TRM of patients with a high score, and this is true for the whole group of patients, for the HLA-identical sibling grafts and for the unrelated grafts. The final COX model included the day +7 score and variables related to the donor, the recipient, the disease and its phase, the transplant, and the year of transplant. Multivariate analysis proved that the day +7 score predicts TRM after adjusting for age, calendar year and donor type. The sensitivity of the day +7 score is 46%: in other words we could identify on day +7 46% of the patients who would subsequently experience TRM. The sensitivity was 75%, thus a low score identified 75% of the patients who would survive the transplant.
One criticism could be that this score is valid in our unit, with BUN and bilirubin values from our central laboratory: we therefore tested the day +7 score on an independent group of children, allografted in a separate hospital, by a different team, using a different central laboratory to test for bilirubin and BUN. Despite the evident bias of comparing children and adults (we could not choose a more disparate group of patients) day +7 score was still highly predictive of transplant mortality, confirming that in the very young age group there are also patients dying of transplant complications who may be identified early after BMT.
There are two additional important issues: (1) why should BUN and bilirubin levels be higher on day +7 in patients who will subsequently die of transplant complications; and (2) can we do anything to change our treatment policy on day +7 to reduce TRM in high risk patients. The two issues are somehow related, because understanding the pathophysiology of organ toxicity would help to design a treatment strategy. Increased bilirubin levels may suggest sub-clinical VOD, in keeping with the Seattle study of this complication. 5 It could also be that patients showing increased bilirubin levels are showing early signs of immune reactivity and of liver GVHD: indeed, bilirubin alone was a good predictor of aGVHD in this study (data not shown), and aGVHD will ultimately lead to transplantrelated complications. As to BUN levels, sub-clinical tubular injury has been reported to be ubiquitous after BMT, 18 suggesting that some degree of renal impairment is seen in all patients. There are several potential pre-renal and renal causes for increased BUN in allogeneic BMT recipients: these include severe infections, dehydration, toxicity of the conditioning regimen and the use of nephrotoxic drugs, such as cyclosporin A, antibiotics and amphotericin B. Creatinine levels were not different on day +7 in low risk vs high risk patients (P = 0.1), but did differ significantly in the two groups on day +15 (P = 0.0001), as one would expect for impending renal insufficiency in patients with higher BUN levels. One could therefore argue that we are simply identifying patients with a lower renal compliance to the conditioning regimen and associated therapy. However, BUN levels were also good predictors of acute GVHD, suggesting that renal toxicity may be one, but not the only explanation for higher levels. In addition, high risk patients had BUN levels у21 mg/dl: therefore we are not comparing patients with or without grossly abnormal BUN levels, but patients with or without sub-clinical renal injury.
Whether also slightly modified BUN levels are the effect of allo-reactivity remains to be determined, although the evident association with aGVHD would suggest a relation with the early cytokine storm described by Hill and coworkers, 14 especially after the demonstration that organ toxicity itself is dependent to some extent on alloreactivity. 14 Finally, can we do anything to change the course of the transplant prospectively in the individual patient, or is the outcome for that patient on day +7 already determined. There are several potential therapeutic options for high risk patients, such as intensified prophylaxis against infections, intensified parenteral nutrition, or the early use of anti-GVHD therapy, such as low-dose anti-lymphocyte globulin (ALG): because of the association of the predictive score with grades III-IV acute GVHD, a pilot study with three doses of ALG given on alternate days from day +7 is ongoing in high risk patients, to test the latter option.
In conclusion, we believe this study strongly suggests that a group of patients at high risk of lethal transplant complications can be identified on day +7 after BMT. Whether this information can be clinically useful to modify the course of the transplant remains to be determined.
